Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
Karen Kelly
No relevant relationships to disclose
Julien Mazieres
No relevant relationships to disclose
Natasha B. Leighl
No relevant relationships to disclose
Fabrice Barlesi
No relevant relationships to disclose
Gerard Zalcman
No relevant relationships to disclose
Michael S. Gordon
Research Funding - GlaxoSmithKline
Karen L. Reckamp
No relevant relationships to disclose
David R. Gandara
No relevant relationships to disclose
Carlos Alberto Gomez-Roca
No relevant relationships to disclose
Jaafar Bennouna
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Byoung Chul Cho
No relevant relationships to disclose
Keunchil Park
No relevant relationships to disclose
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Donald A. Richards
No relevant relationships to disclose
Yuehui Wu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Daniel J. Schramek
Employment or Leadership Position - GlaxoSmithKline
Donna S. Cox
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Olivia S. Gardner
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Vijay Gopal Reddy Peddareddigari
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
George R. Blumenschein
Consultant or Advisory Role - Bayer
Research Funding - Bayer